Startup entity
Every one of those 1 sits in a single category, market-trends. Genmab A/S is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are better corroborated than the beat average, carrying 28 original sources each against 5.5 for the same window.
Last mentioned: Feb 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, market-trends. Genmab A/S is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are better corroborated than the beat average, carrying 28 original sources each against 5.5 for the same window. At 7, the average consequence score sits below the same-window beat average of 7.4. Compass Pathways plc appears in 1 tracked Startup story from February 18, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 39 Startup stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Compass Pathways plc. Shared-story counts are live from our verified record — not editorial picks.
A volatile earnings season is highlighting a sharp divergence in biotech valuations, with Compass Pathways surging on psychedelic therapy success while others face headwinds. Simultaneously, Robinhood's entry into the venture fund IPO market signals a new era of retail access to private-market-style assets.
Compass Pathways plc is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
